CA
NZ
UK
AU
IND
US
…
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -174.32M | -124.70M | -96.02M | -85.98M | -72.19M |
| Net income | -174.32M | -124.70M | -96.02M | -65.51M | -72.12M |
| Selling general administrative | 38.88M | 33.30M | 27.75M | 28.95M | 27.14M |
| Selling and marketing expenses | - | - | 2.58M | - | - |
| Gross profit | -1.64M | -2.46M | -2.58M | 8.09M | 13.62M |
| Reconciled depreciation | 1.64M | 2.46M | 2.91M | 2.41M | 2.96M |
| Ebit | -174.32M | -124.36M | -96.02M | -106.45M | -72.25M |
| Ebitda | -172.69M | -121.90M | -93.43M | -107.92M | -69.29M |
| Depreciation and amortization | 1.64M | 2.46M | 2.58M | -1.47M | 2.96M |
| Non operating income net other | - | - | - | 20.47M | 0.07M |
| Operating income | -179.21M | -129.73M | -104.31M | -106.45M | -72.25M |
| Other operating expenses | 179.21M | 129.73M | 104.31M | 107.37M | 85.87M |
| Interest expense | - | 0.34M | 0.44M | -20.47M | 0.07M |
| Interest income | 10.11M | 9.47M | 7.02M | 2.62M | 0.06M |
| Net interest income | 10.11M | 9.13M | 7.02M | 2.62M | 0.06M |
| Non recurring | - | - | - | 7.18M | - |
| Income tax expense | - | - | - | -20.47M | -0.06M |
| Total revenue | 0.00M | 0.00M | 0.00M | 8.09M | 13.62M |
| Total operating expenses | 177.57M | 127.27M | 101.73M | 107.37M | 85.87M |
| Cost of revenue | 1.64M | 2.46M | 2.58M | - | - |
| Total other income expense net | 4.88M | 5.03M | 8.30M | 20.47M | 0.07M |
| Net income from continuing ops | -174.32M | -124.70M | -90.83M | -85.98M | -72.19M |
| Net income applicable to common shares | - | - | - | -85.98M | -72.19M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 232.54M | 188.66M | 164.94M | 260.25M | 232.38M |
| Other current assets | 17.61M | 8.38M | 6.09M | 5.92M | 8.71M |
| Total liab | 52.53M | 51.42M | 38.46M | 48.59M | 24.17M |
| Total stockholder equity | 180.01M | 137.25M | 126.48M | 211.67M | 208.21M |
| Other current liab | 28.14M | 23.00M | 10.16M | 16.70M | 9.56M |
| Common stock | 0.08M | 0.04M | 0.02M | 0.02M | 0.11M |
| Capital stock | 0.08M | 0.04M | 0.02M | 0.02M | 0.11M |
| Retained earnings | -957.77M | -783.45M | -658.75M | -562.74M | -476.76M |
| Other liab | - | - | - | 0.10M | - |
| Other assets | - | - | 0.00M | - | 2.16M |
| Cash | 59.90M | 80.23M | 74.02M | 155.38M | 119.14M |
| Total current liabilities | 33.47M | 30.26M | 14.52M | 22.51M | 23.60M |
| Current deferred revenue | - | - | - | - | 8.08M |
| Net debt | -38.74M | -56.06M | -47.75M | -126.84M | -117.07M |
| Short term debt | 2.10M | 3.02M | 2.32M | 2.56M | 1.50M |
| Short long term debt total | 21.16M | 24.18M | 26.27M | 28.55M | 2.06M |
| Other stockholder equity | 1137.65M | 920.61M | 785.20M | 774.45M | 684.90M |
| Property plant equipment | - | - | - | 9.66M | 6.46M |
| Total current assets | 205.46M | 157.30M | 129.73M | 219.64M | 222.61M |
| Net tangible assets | - | - | - | 211.67M | 208.21M |
| Short term investments | 127.95M | 68.69M | 49.62M | 58.34M | 88.64M |
| Net receivables | - | - | - | 0.00M | 0.11M |
| Inventory | - | - | - | - | 6.01M |
| Accounts payable | 3.22M | 4.24M | 2.03M | 3.24M | 4.46M |
| Accumulated other comprehensive income | 0.05M | 0.05M | 0.01M | -0.07M | -0.04M |
| Common stock total equity | - | - | - | 0.02M | 0.11M |
| Retained earnings total equity | - | - | - | -562.74M | -476.76M |
| Non currrent assets other | 0.99M | 2.32M | 0.21M | 2.01M | 2.16M |
| Non current assets total | 27.08M | 31.36M | 35.20M | 40.61M | 9.77M |
| Capital lease obligations | 21.16M | 24.18M | 26.27M | 28.55M | 2.06M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -57.39M | -16.09M | 30.49M | -182.76M | -141.25M |
| Change to liabilities | - | - | - | -7.49M | -13.68M |
| Total cashflows from investing activities | -58.45M | -16.09M | 9.69M | 59.16M | -91.09M |
| Net borrowings | -0.72M | -0.47M | 0.00M | - | - |
| Total cash from financing activities | 194.45M | 122.44M | 3.12M | 74.83M | 134.99M |
| Change to operating activities | - | - | - | - | -11.50M |
| Net income | -174.32M | -124.70M | -96.02M | -85.98M | -72.19M |
| Change in cash | -20.30M | 6.34M | -81.37M | 36.01M | -33.87M |
| Begin period cash flow | 82.19M | 75.85M | 155.38M | 121.21M | 155.07M |
| End period cash flow | 61.89M | 82.19M | 74.02M | 157.22M | 121.21M |
| Total cash from operating activities | -156.29M | -100.01M | -94.18M | -97.98M | -77.76M |
| Issuance of capital stock | 196.42M | 127.23M | 75.09M | 72.55M | 134.88M |
| Depreciation | -1.87M | 2.46M | 2.58M | 2.41M | 2.96M |
| Other cashflows from investing activities | - | 0.01M | - | 244.93M | 51.44M |
| Change to inventory | - | - | - | - | -11.50M |
| Change to account receivables | - | - | 0.00M | 0.11M | -0.11M |
| Sale purchase of stock | -1.68M | -5.11M | 0.00M | 72.57M | 134.92M |
| Other cashflows from financing activities | 0.42M | 0.79M | 0.15M | 2.35M | 0.11M |
| Change to netincome | - | - | - | 7.54M | 13.46M |
| Capital expenditures | 1.15M | 0.65M | 1.51M | 3.02M | 1.28M |
| Change receivables | - | - | - | 0.11M | -0.11M |
| Cash flows other operating | - | - | - | -14.79M | -9.33M |
| Cash and cash equivalents changes | - | - | - | 36.01M | -33.87M |
| Change in working capital | -6.82M | 2.85M | -6.34M | -3.69M | -23.04M |
| Stock based compensation | 16.91M | 10.52M | 7.62M | 7.54M | 13.37M |
| Other non cash items | 9.82M | 8.86M | -2.03M | -18.25M | -0.08M |
| Free cash flow | -157.44M | -100.67M | -95.69M | -100.99M | -79.05M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences LLC |
-0.19 2.97% |
6.20 | - | - | 3.65 | 2.51 | 1.16 | -3.69 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
500 Rutherford Avenue, Charlestown, MA, United States, 02129
617 337 4680
121
| Name | Title | Year Born |
|---|---|---|
| Mr. Ian F. Smith A.C.A., ACA, C.P.A., CPA | Exec. Chair | 1966 |
| Mr. Ilan Ganot | Co-founder, Strategic Advisor to the CEO & Director | 1974 |
| Mr. Matthew Bennett Arnold | Co-Founder & Board Member | 1970 |
| Mr. Alexander G. Cumbo | Pres, CEO & Director | 1971 |
| Mr. Gilad David Hayeem | Co-Founder | 1968 |
| Ms. Annie Ganot | Co-Founder & Head of Patient Advocacy | NA |
| Dr. Andrey Juan Zarur Ph.D. | Co-Founder | 1971 |
| Mr. Stephen J. Di Palma M.B.A, M.B.A. | Interim CFO, Treasurer & Principal Accounting Officer | 1959 |
| Mr. Paul Herzich | Chief Technology Officer | NA |
| Mr. David Tyronne Howton Jr., J.D. | Chief Admin. Officer | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...